Following of Myeloid-derived Suppressor Cells (MDSC) in Severe Sepsis: What Relationship With Systemic Inflammatory Syndrome?

University of Limoges (UL)

Status: Terminated

Conditions: Inflammatory Response Syndrome, Systemic; Severe Sepsis

Treatments: Biological: Bone marrow collected during a myelogram carried out for hematological pathology workup; Biological: Residue of blood further to preoperative workup; Biological: Bone marrow collected during myelogram routinely performed during hospitalization in ICU; Biological: Residue of blood further to NFS

Study type: Observational

Funder types: Other

Identifiers

NCT02903082

I16019 (MDSC)

Details and patient eligibility

About

Sepsis remains a major cause of death in developed countries. A better understanding of the mechanisms involved in the regulation of inflammatory and immune response of patients with severe sepsis is an important step that could open the way for new therapeutic approaches.

Enrollment: 68 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient ≥18 years old

• Patient with two criteria of systemic inflammatory response syndrome and one of the four following criteria within 24 hours of hospitalization in ICU:

  • Lactate >4 mmol/L
  • PaO2 / FiO2 <200 in the presence of lung disease as infectious source
  • Vasopressor: adrenaline or noradrenaline ≥0.25 µg/kg/min for at least 6 hours to maintain a systolic blood pressure ≥90 mmHg or mean arterial pressure ≥65 mmHg
  • Thrombocytopenia linked to sepsis with platelet count <100,000 / ml or a decrease ≤50% within 48 hours

Exclusion criteria

• Pregnancy
• progressive solid cancer
• HIV infection
• History of blood or inflammatory disease
• long-term immunosuppressive treatment
• Prior episode of Sepsis in the previous month
• Chronic Dialysis Patient
• Patient under guardianship
• Patient not affiliated with a social security system

Trial design

68 participants in 2 patient groups

Case

Description:

Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome

Treatment:

Biological: Bone marrow collected during myelogram routinely performed during hospitalization in ICU

Biological: Residue of blood further to NFS

Control

Description:

10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.

Treatment:

Biological: Bone marrow collected during a myelogram carried out for hematological pathology workup

Biological: Residue of blood further to preoperative workup